PCVX
Vaxcyte, Inc.
October 6, 2026 · market open
- Rarity
- 2.70
- Peak move
- −13.41%
- Float cap
- $9.4B
Vaxcyte, Inc. is a clinical-stage vaccine innovation company that engineers high-fidelity vaccines against bacterial diseases. It uses its XpressCF cell-free protein synthesis platform to develop conjugate and protein vaccine candidates for adult and pediatric indications. Its pipeline includes broad-spectrum pneumococcal conjugate vaccine candidates designed to prevent invasive pneumococcal disease, pneumonia, and related infections.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
7 events · 1 from SEC or newswire · 0 timed with the moveanalyst_ratingJefferies maintained a Buy rating on Vaxcyte with a $146 price target and Mizuho Securities maintained a Buy rating with a $163 price target following the positive VAX-31 OPUS-1 Phase 3 data.
- Key event
equity_offeringVaxcyte commenced underwritten public offerings of $500 million of common stock and pre-funded warrants, alongside a separate $500 million convertible senior notes offering due October 15, 2032, with 30-day over-allotment options of up to $75 million each and interest rate and conversion premium to be set at pricing, to fund VAX-31 clinical development, manufacturing scale-up and launch preparation.
- Key event
executive_remarkVaxcyte CEO Grant Pickering called the VAX-31 OPUS-1 data a new benchmark for the pneumococcal conjugate vaccine class and the clinical cornerstone of a planned Biologics License Application, with two more adult Phase 3 readouts expected in the first half of 2027 and a US filing targeted for the first half of 2028.
analyst_ratingNeedham raised its price target on Vaxcyte to $122 from $110 while maintaining a Buy rating, following the positive Phase 3 OPUS-1 results for VAX-31.
- Key event
clinical_readoutVaxcyte reported positive topline data from the pivotal Phase 3 OPUS-1 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, meeting all 32 prespecified co-primary immunogenicity endpoints in adults 50 and older, with noninferiority for shared serotypes versus Pfizer's Prevnar 20 (PCV20) and Merck's Capvaxive (PCV21) and superiority for three VAX-31-unique serotypes plus cross-reactive 20B; a BLA filing is planned for H1 2028, and the company hosted a webcast and conference call with a related slide presentation.
analyst_ratingGuggenheim analyst Seamus Fernandez raised the price target on Vaxcyte to $125 from $116 while maintaining a Buy rating, calling the adult VAX-31 OPUS-1 Phase 3 a major win.
clinical_readoutVaxcyte announced it will host a webcast and conference call on October 5, 2026 at 8:00 a.m. ET to present topline data from the pivotal adult Phase 3 OPUS-1 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate.